JP2022529311A5 - - Google Patents
Info
- Publication number
- JP2022529311A5 JP2022529311A5 JP2021556882A JP2021556882A JP2022529311A5 JP 2022529311 A5 JP2022529311 A5 JP 2022529311A5 JP 2021556882 A JP2021556882 A JP 2021556882A JP 2021556882 A JP2021556882 A JP 2021556882A JP 2022529311 A5 JP2022529311 A5 JP 2022529311A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- deuterium
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824144P | 2019-03-26 | 2019-03-26 | |
| US62/824,144 | 2019-03-26 | ||
| PCT/US2020/024746 WO2020198379A1 (en) | 2019-03-26 | 2020-03-25 | Tyk2 pseudokinase ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529311A JP2022529311A (ja) | 2022-06-21 |
| JP2022529311A5 true JP2022529311A5 (enExample) | 2023-03-31 |
| JP7595582B2 JP7595582B2 (ja) | 2024-12-06 |
Family
ID=72612101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556882A Active JP7595582B2 (ja) | 2019-03-26 | 2020-03-25 | Ｔｙｋ２偽キナーゼリガンド |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11780842B2 (enExample) |
| EP (1) | EP3946350A4 (enExample) |
| JP (1) | JP7595582B2 (enExample) |
| KR (1) | KR20220004641A (enExample) |
| CN (1) | CN113874021B (enExample) |
| AU (1) | AU2020247990A1 (enExample) |
| BR (1) | BR112021019070A2 (enExample) |
| CA (1) | CA3134814A1 (enExample) |
| EA (1) | EA202192625A1 (enExample) |
| IL (1) | IL286635A (enExample) |
| MX (1) | MX2021011723A (enExample) |
| SG (1) | SG11202110523XA (enExample) |
| WO (1) | WO2020198379A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| CA3132632A1 (en) * | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| CA3134814A1 (en) | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| JP7635228B2 (ja) | 2019-11-08 | 2025-02-25 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| EP4214215A1 (en) * | 2020-09-16 | 2023-07-26 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
| CN114591351B (zh) * | 2020-12-03 | 2023-12-05 | 成都科岭源医药技术有限公司 | 一种多环化合物及其制备方法和用途 |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
| JP2026512838A (ja) * | 2023-03-31 | 2026-04-21 | 北京普祺医薬科技股▲分▼有限公司 | 大環化合物、医薬組成物及びその使用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7557110B2 (en) | 2003-02-28 | 2009-07-07 | Teijin Pharma Limited | Pyrazolo[1,5-A] pyrimidine derivatives |
| BRPI0616985B1 (pt) | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| US7517882B2 (en) | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
| ME03376B (me) * | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| ES2933350T3 (es) | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| PT3371190T (pt) | 2015-11-06 | 2022-07-08 | Incyte Corp | Compostos heterocíclicos como inibidores de pi3k-gamma |
| US10689400B2 (en) | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| KR102477063B1 (ko) | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| TW202515876A (zh) | 2017-03-08 | 2025-04-16 | 日商武田藥品工業股份有限公司 | Tyk2抑制劑及其用途 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018213365A1 (en) | 2017-05-15 | 2018-11-22 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| SI3658557T1 (sl) | 2017-07-28 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Zaviralci TYK2 in njihova uporaba |
| JP7179161B2 (ja) | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| AR117177A1 (es) | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| JP2022519696A (ja) | 2019-02-07 | 2022-03-24 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| CA3132632A1 (en) | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| CA3134814A1 (en) | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| JP7635228B2 (ja) | 2019-11-08 | 2025-02-25 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
-
2020
- 2020-03-25 CA CA3134814A patent/CA3134814A1/en active Pending
- 2020-03-25 KR KR1020217034394A patent/KR20220004641A/ko not_active Ceased
- 2020-03-25 MX MX2021011723A patent/MX2021011723A/es unknown
- 2020-03-25 EP EP20777561.0A patent/EP3946350A4/en active Pending
- 2020-03-25 US US17/441,788 patent/US11780842B2/en active Active
- 2020-03-25 BR BR112021019070A patent/BR112021019070A2/pt not_active Application Discontinuation
- 2020-03-25 AU AU2020247990A patent/AU2020247990A1/en not_active Abandoned
- 2020-03-25 WO PCT/US2020/024746 patent/WO2020198379A1/en not_active Ceased
- 2020-03-25 JP JP2021556882A patent/JP7595582B2/ja active Active
- 2020-03-25 EA EA202192625A patent/EA202192625A1/ru unknown
- 2020-03-25 SG SG11202110523XA patent/SG11202110523XA/en unknown
- 2020-03-25 CN CN202080038590.0A patent/CN113874021B/zh active Active
-
2021
- 2021-09-23 IL IL286635A patent/IL286635A/en unknown
-
2023
- 2023-08-28 US US18/457,070 patent/US20230406858A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529311A5 (enExample) | ||
| JP2022519696A5 (enExample) | ||
| JP2022553841A5 (enExample) | ||
| JP2015502387A5 (enExample) | ||
| JP2016515096A5 (enExample) | ||
| JP2019531279A5 (enExample) | ||
| JP2023518044A5 (enExample) | ||
| RU2019116514A (ru) | Ингибиторы magl | |
| JP2012529535A5 (enExample) | ||
| JP2022547617A5 (enExample) | ||
| JP2024543512A5 (enExample) | ||
| ZA200609277B (en) | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | |
| JP2018504437A5 (enExample) | ||
| RU2015149767A (ru) | Дейтерированные диаминопиримидиновые соединения и фармацевтические композиции, содержащие такие соединения | |
| JP2022552445A5 (enExample) | ||
| JP2013533883A5 (enExample) | ||
| JP2017522277A5 (enExample) | ||
| JP2022532877A5 (enExample) | ||
| JP2016514719A5 (enExample) | ||
| JP2010521443A5 (enExample) | ||
| JP2021522262A5 (enExample) | ||
| JP2024512931A5 (enExample) | ||
| RU2016115487A (ru) | Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda | |
| JP2022529518A5 (enExample) | ||
| JP2020521766A5 (enExample) |